TBVAC2020 – Advancing novel and promising TB vaccine candidates from discovery to preclinical and early clinical development

TBVAC2020 aims to innovate and diversify the current TB vaccine and biomarker pipeline while at the same time applying portfolio management using gating and priority setting criteria to select as early as possible the most promising TB vaccine candidates, and accelerate their development.
The proposed approach and involvement of many internationally leading groups in the TB vaccine and biomarker area in TBVAC2020 fully aligns with the Global TB Vaccine Partnerships.

Details

Status:

  • inactive

Research Focus:

  • Medicine and Health

Project Coordination:

Stichting TuBerculosis Vaccine Initiative
(TBVI)

Partners:

Statens Serum Institut , denmark
SCIENSANO, belgium
Universiteit Gent, Belgium
Bangor University, United Kingdom
Universität Ulm, Germany
Institut Pasteur, France
Centre National De La Recherche Scientifique CNRS, France
Universidad de Zaragoza, Spain
Universite de Geneve, Switzerland
Eidgenoessische Technische Hochschule Zuerich, Switzerland
University College Dublin, National University Of Ireland, Dublin, Ireland
Yonsei University, South Korea
Stichting Biomedical Primate Research Center, Netherlands
Department of Health, United Kingdom
Universität Zürich, Switzerland
Institut De Investigacio En Ciencies De La Salut Germans Trias I Pujol, Spain
United Kingdom research and Innovation, United Kingdom
London School Of Hygiene And Tropical Medicine Royal Charter, United Kingdom
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone Di Palermo, Italy
Imperial College Of Science Technology And Medicine, United Kingdom
Academisch Ziekenhuis Leiden, Netherlands
Universite Libre de Bruxelles, Belgium
Istituto Nazionale Per Le Malattie Infettive Lazzaro Spallanzani-Istituto Di Ricovero E Cura A Carattere Scientifico, Italy
The University of Sydnexy, Australia
The Chancellor, Masters And Scholars Of The University Of Oxford, United Kingdom
The Secretary Of State For Environment, Food And Rural Affairs, United Kingdom
Centre Hospitalier Universitaire Vaudois, Switzerland
Institut Pasteur De Lille Fondation, France
Universite de Lausanne, Switzerland
Universitat Basel, Switzerland
Istituto Superiore Di Sanita, Italy
AERAS GLOBAL TB VACCINE FOUNDATION, United States
International Tuberculosis Research Center, South Korea
Glaxosmithkline Biologicals SA, Belgium
TRANSGENE SA, France
Friedrich Loeffler Institut – Bundesforschungsinstitut Fuer Tiergesundheit, Germany
University Of Strathclyde, United Kingdom

Countries:

Germany (Bavaria), South Africa

Duration:

01/01/2015
– 30/06/2019

Budget:

18200000 EUR

URL: